⌕
Dexcom · DXCM · Nasdaq
Tenet 55 · Mixed
Compare
$82.04+0.53%At closeTenet 55 · Mixed
$82.04+0.43 (+0.53%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$81.98−0.06 (−0.07%)
After hours: Nov 17, 2026, 6:23 PM ET

Dexcom (DXCM) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is DXCM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● MarketBeatNov 18, 2026 · 02:13 ET
DexCom Sees Record New Patients in 2026 as Medicare Coverage Decision Looms

DexCom NASDAQ: DXCM expects a record number of new patients in 2026 and is preparing for a potential expansion of Medicare coverage for continuous glucose monitoring, executives said during a discussion hosted by Jefferi…

DXCM +0.5% todayRead at source ↗
● Seeking AlphaNov 17, 2026 · 14:42 ET
DexCom, Inc. (DXCM) Presents at Jefferies Global Healthcare Conference 2026 Transcript

DexCom, Inc. (DXCM) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

DXCM +0.5% todayRead at source ↗
● Defense WorldNov 17, 2026 · 08:04 ETEARNINGS EXPECTED BY FEB 8
DexCom, Inc. $DXCM Shares Sold by Aberdeen Group plc

Aberdeen Group plc cut its holdings in DexCom, Inc. (NASDAQ: DXCM) by 14.8% during a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3…

DXCM +0.5% todayRead at source ↗
● Defense WorldNov 16, 2026 · 03:51 ETEARNINGS EXPECTED BY FEB 8
Commonwealth Equity Services LLC Purchases 10,738 Shares of DexCom, Inc. $DXCM

Commonwealth Equity Services LLC raised its position in DexCom, Inc. (NASDAQ: DXCM) by 18.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 70,241 shares of the medical device …

DXCM +0.5% todayRead at source ↗
● Zacks Investment ResearchNov 13, 2026 · 08:25 ET
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

DexCom's G7 15 Day adoption, international expansion and margin gains support its growth prospects, though competition and rising investments pose challenges.…

DXCM +0.5% todayRead at source ↗
● Business WireNov 10, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Dexcom Announces Upcoming Conference Presentation

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026.The live …

DXCM +0.5% todayRead at source ↗
● Zacks Investment ResearchNov 3, 2026 · 13:01 ET
DexCom to Launch 15-Day G7 CGM System in Canada This November

DXCM's upcoming Canadian launch of the G7 15 Day CGM, offering longer sensor wear and improved convenience, could boost international growth and patient access.…

DXCM +0.5% todayRead at source ↗
● Business WireNov 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes Day, creating a platf…

DXCM +0.5% todayRead at source ↗
● Seeking AlphaNov 1, 2026 · 23:27 ET
DexCom: Improving Patient Access Makes It A Long-Term Buy

DXCM's recurring sensor model synergizes nicely with wider diabetes access thanks to Medicare. In fact, broader Medicare coverage could expand their overall addressable market, as long as DXCM is able to execute on that …

DXCM +0.5% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 12:01 ETEARNINGS EXPECTED BY FEB 8
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise

DXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.…

DXCM +0.5% todayRead at source ↗
● Seeking AlphaOct 29, 2026 · 21:28 ETEARNINGS EXPECTED BY FEB 8
DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript

DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript…

DXCM +0.5% todayRead at source ↗
● MarketBeatOct 29, 2026 · 19:15 ETEARNINGS EXPECTED BY FEB 8
What DexCom (DXCM) Said on Its Q3 Earnings Call

DexCom NASDAQ: DXCM reported third-quarter 2026 revenue of $1.34 billion, up 11% from a year earlier on both a reported and organic basis, as U.S. growth, market-share gains and manufacturing improvements supported highe…

DXCM +0.5% todayRead at source ↗
● Zacks Investment ResearchOct 29, 2026 · 18:16 ETEARNINGS EXPECTED BY FEB 8
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates

DexCom (DXCM) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.61 per share a year ago.…

DXCM +0.5% todayRead at source ↗
● BenzingaOct 29, 2026 · 17:43 ETEARNINGS EXPECTED BY FEB 8
DexCom Q3 2026 Earnings Call Transcript

DexCom (NASDAQ:DXCM) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.…

DXCM +0.5% todayRead at source ↗
● Investors Business DailyOct 29, 2026 · 16:19 ETEARNINGS EXPECTED BY FEB 8
Diabetes Wearable-Maker Handily Beats Earnings Views, Hikes Sales Guide

Diabetes wearables-maker Dexcom topped third-quarter earnings forecasts Thursday and reported in-line sales. Dexcom stock was little moved.…

DXCM +0.5% todayRead at source ↗
● Business WireOct 29, 2026 · 16:03 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 8
Dexcom Reports Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports Third Quarter 2026 Financial Results.…

DXCM +0.5% todayRead at source ↗
● Business WireOct 28, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November

BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) will be available in …

DXCM +0.5% todayRead at source ↗
● PRNewsWireOct 27, 2026 · 15:29 ET
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p…

DXCM +0.5% todayRead at source ↗
● Zacks Investment ResearchOct 26, 2026 · 15:00 ETEARNINGS EXPECTED BY FEB 8
DexCom Gears Up to Report Q3 Results: How to Play the Stock?

DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.…

DXCM +0.5% todayRead at source ↗
● GuruFocusOct 21, 2026 · 17:49 ET
DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors

On October 21, 2026, DexCom Inc (DXCM) shares fell 6.4% to a current price of $80.26. This decline comes amidst a 52-week range of $54.11 to $92.59, highlightin…

DXCM +0.5% todayRead at source ↗
● Zacks Investment ResearchOct 20, 2026 · 11:50 ETEARNINGS EXPECTED BY FEB 8
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study

DXCM's G7 delivers strong results in the CONNECT study, improving A1C levels and glucose control in non-insulin users with Type 2 diabetes, supporting CGM adoption.…

DXCM +0.5% todayRead at source ↗
● Defense WorldOct 20, 2026 · 04:55 ET
DexCom (NASDAQ:DXCM) EVP Michael Jon Brown Sells 1,700 Shares of Company Stock

DexCom, Inc. (NASDAQ: DXCM - Get Free Report) EVP Michael Brown sold 1,700 shares of the business's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total value …

DXCM +0.5% todayRead at source ↗
● Seeking AlphaOct 17, 2026 · 23:41 ETEARNINGS EXPECTED BY FEB 8
DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence, especially for non-insulin Type 2 diabetes. The G7 15-Day sensor transition cut manufacturing costs,…

DXCM +0.5% todayRead at source ↗
● Business WireOct 14, 2026 · 17:10 ETEARNINGS EXPECTED BY FEB 8
Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England …

DXCM +0.5% todayRead at source ↗
● Business WireOct 6, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading

SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) pro…

DXCM +0.5% todayRead at source ↗
● Business WireSep 28, 2026 · 02:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 8
Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

MILAN--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its “Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” in advance of the 62nd …

DXCM +0.5% todayRead at source ↗
● Business WireSep 14, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Dexcom Promotes Jereme Sylvain to Chief Operating Officer

SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.…

DXCM +0.5% todayRead at source ↗
● Business WireSep 10, 2026 · 16:15 ETCOMPANY'S OWN WORDS
Dexcom Appoints Glenn Boehnlein to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein i…

DXCM +0.5% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 8. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

NVDA31−0.4%
WDAY4−5.8%
EG3−2.0%

Article counts from the last market-wide feed page, across every symbol we track and not just DXCM · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.